Amiodarone hepatotoxicity. A clinicopathologic study of five patients.
Five patients had amiodarone hepatotoxicity detected on routine biochemical monitoring. Symptoms attributable to hepatotoxicity were minimal or absent; reversible hepatomegaly was seen in two patients, whereas three patients had signs of nonhepatic amiodarone toxicity before or with hepatotoxicity. Serum aminotransferase levels were elevated in all patients and alkaline phosphatase levels in four; no patient had hyperbilirubinemia or prolongation of the prothrombin time. Light microscopy showed steatosis, cellular degeneration, and cellular necrosis in the biopsy samples of four patients, whereas the fifth patient's sample had a granulomatous injury pattern. Electron microscopic study of liver tissue done in two patients showed phospholipid-laden lysosomal lamellar bodies. These findings suggest that both toxic and hypersensitivity liver injury can occur in response to amiodarone. The presence of phospholipid-laden lysosomal lamellar bodies may help differentiate amiodarone hepatotoxicity from alcoholic liver disease or other causes of hepatic steatosis.
D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000638:Amiodarone / Q000009:adverse effects*; D001219:Aspartate Aminotransferases / Q000097:blood; D001572:Benzofurans / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury; D005234:Fatty Liver / Q000139:chemically induced; D005260:Female; D006529:Hepatomegaly / Q000139:chemically induced; D006801:Humans; D008099:Liver / Q000648:ultrastructure; D008107:Liver Diseases / Q000473:pathology; D008297:Male; D008875:Middle Aged
D001572:Benzofurans; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D000638:Amiodarone